MicroRNAs and Other Non-Coding RNAs: Implications for Cancer Patients

Munker, Reinhold; Calin, George A.

doi:10.1007/978-94-007-4655-8_1

MicroRNA in Cancer 2012

DOI: 10.1007/978-94-007-4655-8_1

|View full text |Cite

MicroRNAs and Other Non-Coding RNAs: Implications for Cancer Patients

Reinhold Munker

George A. Calin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cell-free RNA, micro-RNA & exosomes Cf-RNAs, including coding message RNA (mRNA), noncoding large ribosomal RNA (rRNA) and noncoding small micro-RNA (miRNA) are now of growing importance as biomarkers for cancer and other diseases [51][52][53][54][55][56][57][58][59][60]. RNA-containing exosomes and other secreted vesicles are also emerging as potentially potent targets for molecular diagnostic applications [61][62][63].…”

mentioning

confidence: 99%

Detecting cancer biomarkers in blood: challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids

Lewis

Heineck

Heller

2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

As we move into the era of individualized cancer treatment, the need for more sophisticated cancer diagnostics has emerged. Cell-free (cf) nucleic acids (cf-DNA, cf-RNA) and other cellular nanoparticulates are now considered important and selective biomarkers. There is great hope that blood-borne cf-nucleic acids can be used for 'liquid biopsies', replacing more invasive tissue biopsies to analyze cancer mutations and monitor therapy. Conventional techniques for cf-nucleic acid biomarker isolation from blood are generally time-consuming, complicated and expensive. They require relatively large blood samples, which must be processed to serum or plasma before isolation of biomarkers can proceed. Such cumbersome sample preparation also limits the widespread use of powerful, downstream genomic analyses, including PCR and DNA sequencing. These limitations also preclude rapid, point-of-care diagnostic applications. Thus, new technologies that allow rapid isolation of biomarkers directly from blood will permit seamless sample-to-answer solutions that enable next-generation point-of-care molecular diagnostics.

show abstract

mentioning

confidence: 99%

Detecting cancer biomarkers in blood: challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids

Lewis

Heineck

Heller

2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

MicroRNAs and Other Non-Coding RNAs: Implications for Cancer Patients

Cited by 1 publication

References 50 publications

Detecting cancer biomarkers in blood: challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids

Detecting cancer biomarkers in blood: challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids

Contact Info

Product

Resources

About